Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

“…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”

Blocking of MC1R, MC2R or MC5R causes a decrease in the enucleation ratio of erythrocytes. by Eriko Simamura (720229)

“…The enucleation ratio was decreased in the erythroblasts treated with anti-MC1R nAb, anti-MC2R nAb or anti-MC5R nAb. *, <i>P <</i> 0.0001, each point versus control. n = 3; error bars, s.e.m. …”

rVλ6Wil fibrils cause a decrease in cardiomyocytes MTT reduction without inducing cell death. by Helen P. McWilliams-Koeppen (116503)

“…(C) Cell number, quantified using crystal violet (black) did not decrease over 72 h of incubation with 1 μM rVλ6Wil fibrils despite a decrease in MMT reduction (grey; n = 3 samples per time point). …”

Effects of Cu (5 µM) pretreatment on Hcy-induced decrease in cell viability and LDH release. by Daoyin Dong (424519)

Diverse stress conditions trigger a rapid and dramatic decrease in miR-520b-3p and a corresponding increase in ATF5 mRNA over time in HeLa cells. by Kari A. Gaither (9046190)

Chronic intestinal inflammation persistently decreases frequency of mucosal CD5⁺ B cells. by Yoshiyuki Mishima (842248)

Chronic intestinal inflammation persistently decreases frequency of mucosal CD5⁺ B cells. by Yoshiyuki Mishima (842248)

AILV-V RNA-2 accumulation varies in the same leaf, progressively decreasing moving to the successive leaf. by Elisa Santovito (575029)

SARS-CoV-2 inhibits SG formation and decreases expression of G3BP1. by Stacia M. Dolliver (13822801)

Fig 5 - by Arjen Tilstra (6915227)

A homozygous point mutation in the <i>Mrps34</i> gene causes a decrease in the MRPS34 protein. by Tara R. Richman (713532)

“…The 5′- and 3′-untranslated regions are shown as grey boxes and the predicted mitochondrial targeting sequence is shown as a black box (predicted using MitoProtII, [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005089#pgen.1005089.ref040" target="_blank">40</a>]). …”

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects:

Molecular Dynamics Characterization of Five Pathogenic Factor X Mutants Associated with Decreased Catalytic Activity by Safwat Abdel-Azeim (153436)

Subjects: